



Annual General Meeting

November 2017

ASX: MEB
OTCQB: MDBIF

DISCLAIMER



FORWARD LOOKING STATEMENTS

The purpose of the presentation is to provide an update of the business of Medibio Limited (**ASX:MEB**) (**OTCQB: MDBIF**). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification.

Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Medibio Limited and should not be relied upon as an independent source of information. Please contact Medibio Limited and/or refer to the Company's website for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified.

None of Medibio Limited, or any of its affiliates or associated companies (or any of their officers, employees, contractors or agents (the Relevant Persons)) makes any representation or warranty as to the accuracy, completeness or reliability of the information, or the likelihood of fulfilment of any forward looking statement or any outcomes expressed or implied in any forward looking statements.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks,

uncertainties and other factors, many of which are outside Medibio Limited's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks.

Because actual results could differ materially to assumptions made and Medibio Limited's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. Except as required by applicable law or the ASX listing rules, the Relevant Persons disclaim any obligation or undertaking to publicly update any statements in this presentation, whether as a result of new information or future events.

This presentation should not be relied on as a recommendation or forecast by Medibio Limited. Nothing in this presentation constitutes investment advice or should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

INVESTMENT HIGHLIGHTS

MEDIBIO'S FIRST PRODUCT RELEASE

Major transition of focus on delivery of product for the market and with clear product development plan

INVESTMENT IN HUMAN CAPITAL

Identification of best quality team assembled for future success

COMPLETION OF STRATEGIC PLANNING SESSION

Developed strategic plan that will carry business for 5 year growth plan

PRODUCT INTEGRATION AND LAUNCH

Developing the first objective testing system to diagnosis depression and other mental health disorders

EXPANDING PATENTED PANEL OF BIOMARKERS

Leveraging autonomic, circadian and sleep biomarkers to objectively characterize broad spectrum mental illness

CLOUD-BASED PLATFORM ABLE TO OPERATE ON ANY SYSTEM

System and device agnostic - aim for a cost-effective delivery of information to healthcare providers or consumers

SUPERIOR VALUE PROPOSITION

- Objective approach to screening, diagnosing, monitoring, and management of Mental Illness

CLINICAL VALIDATION STUDIES WITH LEADING RESEARCH INSTITUTIONS

- Johns Hopkins, Mayo Clinic, Emory University, Ottawa University, BMRI

REGULATORY PROCESS UNDERWAY

- FDA clearance and CE Mark certification

PARTNERS ACROSS VERTICALS WITH HIGH INTEREST TO COMMERCIALIZE

- Partnership opportunities under consideration include Wearables, Sleep Analysis and Treatment, Digital Health and Telepsych

MAJOR ACHIEVEMENTS

NEWLY APPOINTED CEO

US Headquarters recently created with a renewed focus and expertise in medtech

HIGH PROFILE BOARD OF DIRECTORS

Strategically assembled board with a common focus and background of success

COMMERCIALISATION AT THE CORE OF GROWTH

Strategy and vision set for the company to commercialise for near term opportunities

RESOLUTION OF OUTSTANDING LEGACY MATTERS

Leadership, governance and share registry matters addressed

EXPANDING PATENT BASE

Leveraging autonomic, circadian and sleep biomarkers to objectively characterize broad spectrum mental illness

RIGHT TEAM FOR THE JOB

Assembled top industry experts in roles that contribute directly to the strategy of the business

PARTNERSHIP WITH MAJOR ACADEMIC CENTER OF EXCELLENCE

Mayo Clinic two part agreement covering clinical studies as well as a strategic partnership and development agreement

FIRST REVENUE WITH MAJOR PHARMA PARTNER

Otsuka agreement gives additional validation to our science

FIRST INDEPENDENT VALIDATION STUDY PUBLISHED

Providing a roadmap for a rich pipeline of clinical evidence

COMPLETION OF EXPLORATORY STUDY LEADING TO CONFIRMATORY IN PROGRESS

FDA De Novo application progressing with a clear path to completion

ON TRACK FOR CE MARK

Successful QMS system in place and being utilised for completion of upcoming QMS audit completion

RECENT SUCCESSFUL CAPITAL RAISE

Oversubscribed \$14M raise closed to ensure full capitalisation

CORPORATE STRUCTURE


CAPITAL STRUCTURE (ASX:MEB) (OTCQB:MDBIF)

(amounts shown in AUD\$)

Market Cap	\$53.7M
Share Price <i>as of 28 November 2017</i>	\$0.32
Shares on Issue	197.9M
Market Cap (fully diluted)	\$71.2M
Share Price <i>as of 28 November 2017</i>	\$0.32
Fully diluted shares <i>(per November 14, 2017 Appendix 3B)</i>	224.0M
Cash Available	\$20.8M

(September 30, 2017 cash balance plus \$17.5M anticipated inflow over 9 months from October 2017 completed capital raise, R&D rebate received, and stock option exercise, & partly paid shares)

SUBSTANTIAL SHAREHOLDERS




Medibio will be the company that changes the way the world sees mental health.

Medibio is a mental health technology company focused on standardized, objective measures to improve the screening, diagnosis, monitoring, and management of mental health conditions based on biomarkers and psycho-social inputs.


SCIENCE BASED ON 16 YEARS OF CLINICAL RESEARCH

- Research initiated 16 years ago at University of Western Australia to test the theory that mental state is linked to autonomic nervous system (ANS), circadian and sleep disturbance
- Morphologic analysis of circadian heart rate waveforms (CHR) gives objective indications of 'core' physiological differences between different forms of mental illness such as anxiety and depression
- All serious mental illness (SMI) are associated with ANS and wider neuroendocrine dysregulation (especially affective disorders) and abnormalities in circadian regulation.
- Evidence of the state-dependent relationship between psychiatric status and CHR has come from serial monitoring of patients undergoing treatment – from individuals monitored days, weeks, months and years apart.


NORMAL



DEPRESSION



ANXIETY



24 hour heart-rate

BIOMARKERS PROVIDE RICH CHARACTERIZATION OF MENTAL STATE


HEART-RATE

AUTONOMIC FUNCTION

ACTIVITY

SLEEP

CIRCADIAN PATTERNS



THE REASON WHY **PREVALENCE**

26%
ADULTS IN US

Leading cause of disability in the
US

1 in 4
with Mental Health Diagnosis

350 MILLION
suffer from depression

1 in 13
suffer from anxiety

7.7M

PTSD sufferers in the United States
alone, or **3.5%** of the population

21M

Suicide attempts from Mental Illness

27%
ADULTS IN EUROPE

REFERENCES

- NIMH [article](#)
- World Health Organization. (WHO 2011a).
Global status report on non-communicable diseases 2010.
Geneva: WHO World Mental Health Day 2015

OUR PRODUCTS

CONSUMER *unregulated*

- Screening
- Risk Stratification
- Wellness Scoring
- Wellness Monitoring

MENTAL **WELLNESS**

MEDICAL *regulated*

- Pre-Screening
- Differential Diagnosis
- Treatment Adherence Tracking
- Treatment Efficacy Monitoring

MENTAL **ILLNESS**

OUR PRODUCTS

We use the body's biometric data to objectively measure mental health.

HEALTHCARE PROVIDER *Diagnostic Aid*



PATIENT *Monitoring & Scoring*



OBJECTIVE DATA TO DRIVE CLINICAL OUTCOMES

Today's Approach *Subjective Measures*

*Symptom Based
Diagnosis Screeners:*

- DSM-5
- PHQ-9
- GAD-7
- GHQ-12
- PC-PTSD
- MDQ / MSS

*Better **Screening***

*Better **Diagnoses***

*Better **Treatments***

*Better **Monitoring***

*Better **Outcomes***


Medibio Data

Objective Measures

Biometric Markers:


- Circadian Heart Rate
- Sleep Cycles
- Autonomic System
- Actigraphy

PATIENT JOURNEY



OUR MODEL

**OBJECTIVE DATA TO
DRIVE CLINICAL
OUTCOMES**



SIGNIFICANT VALIDATION SUPPORTING TECHNOLOGY

ACCURACY

STUDY OUTLINE

PARTNER

86%

DEPRESSION

Retrospective Study, 889 patients (2 Nov 2016)

OTTAWA UNIVERSITY

81%

DEPRESSION

Prospective Study, 26 patients (21 Dec 2016)

JOHNS HOPKINS

78-98%

DEPRESSION, ANXIETY DISORDER, SCHIZOPHRENIA

Various historical studies (Medibio)

PEER REVIEWED

86-95%

SLEEP STAGING USING ECG DATA:

7500 patients completed 24 June 2016

JOHNS HOPKINS

Versus 33-50% - Diagnostic accuracy in the Primary Care Setting⁽¹⁾

(1) Depression in Primary Care Vol. 1: U.S. Department of Health

PATH TO REVENUE

Current primary care screening environment alone presents an **\$875M** opportunity. Another **50%** of population are unscreened. This test will be as common as taking a patient's vital signs.

PRODUCT	Per Patient Revenue	Estimated Market Size	Estimated Market Potential
EARLY DETECTION SCREENING MEDIBIO-ID	\$15-\$20 per patient session	43.8 million U.S. adults suffer mental illness annually	\$875 million U.S. Market
ACCURATE DIAGNOSIS MEDIBIO-DX	\$180-\$240 patient/ annually	21.9 million U.S. adults are diagnosed (50% rate)	\$5.3 Billion U.S. Market
RIGHT DRUG TREATMENT MEDIBIO-RX	\$180-\$240 patient/ annually	15.3 million U.S. adults accurately treated (70%)	\$3.7 Billion U.S. Market

Does **not** include treatment, prevention, medication management, data, as well as all other market (paediatric and adolescent) and applications of our system.

UPCOMING NEWS

TIMING	MILESTONE	STATUS
Q4, 2016	Pilot Study Validation Johns Hopkins University (Major Depressive Disorder n=20)	✓
Q1, 2017	Strategic Research Partnership - Emory PTSD	✓
Q2, 2017	Completion of John Hopkins University Validation Study (Major Depressive Disorder n=60) Publishing of Peer-reviewed paper - Emory University (PTSD)	✓
Q3, 2017	Presentation of independent paper - University of Ottawa (Major Depressive) Announcement of results from the John Hopkins University Exploratory Study (Major Depressive Disorder n=60). Commencement of Confirmatory Study to provide data for FDA Submission (n=200)	✓
Q3, 2017	Agreement with FDA on subject numbers required for depression confirmatory study Commencement of Confirmatory Study to provide data for FDA Submission (n=200)	
Q4, 2017	CE Mark submission (Platform, Major Depressive Disorder diagnostic aid) QMS Audit for CE Mark	
Q1, 2018	CE Mark and QMS certification (Platform, Major Depressive Disorder diagnostic aid)	
Q2, 2018	FDA submission (Major Depressive Disorder diagnostic aid)	


Addendum

medibio 
INNOVATION IN MIND


OBJECTIVE ASSESSMENT OF THERAPY EFFECTIVENESS

Case Study 1

- Individual diagnosed with Generalized Anxiety Disorder (GAD)
- Re-evaluated 10 days following effective psychotherapy treatment



Biometrics normalize with effective treatment



COMPANY
OUR BOARD



CHRIS INDERMAUR

Chairman
Seasoned ASX Chair



DR. ADAM DARKINS

Deputy Chairman
(Incoming Chairman)
Telehealth Thought Leader



**DR. FRANKLIN
PRENDERGAST**

Non-Executive Director
Healthcare Luminary




MICHAEL PHELPS

Non-Executive Director
*World Class Athlete and Mental
Health Advocate*



PATRICK KENNEDY

Non-Executive Director
*Former US Congressman and
Mental Health Advocate*



ANDREW MAXWELL

Non-Executive Director
Former Biotech CEO



JACK COSENTINO

Executive Director
CEO & Managing Director



PETER CARLISLE

Board Alternate
Attorney and Leading Sports Agent

MICHAEL PHELPS

A photograph of Michael Phelps swimming in a pool. He is wearing a white swim cap with "NBAC" and "NP" on it, and blue goggles. He is in a streamlined position, with his arms extended forward. The water is splashing around him, and the background is blurred. The text is overlaid on the bottom half of the image.

"I have personally experienced Medibio's technology and believe it can help make a profound impact in diagnosing mental health and empowering people to seek the help and support they may need"

Michael Phelps

photo credit "Aqua Sphere"

PATRICK KENNEDY

A photograph of Patrick Kennedy, a man with short brown hair, wearing a light blue zip-up sweater over a blue polo shirt. He is leaning on a wooden railing with his hands clasped, looking directly at the camera with a serious expression. The background is a blurred outdoor setting with trees and a building.

“I see a future where everyone who needs mental health care gets it. We must end the separate and unequal treatment of mental health and addiction, and ensure each of us is able to achieve a full, meaningful life.”

Patrick Kennedy
Founder, The Kennedy Forum

photo : NBC News